ARDS - MediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterol

MediciNova (NASDAQ:MNOV) received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent is expected to expire no earlier than July 2034. The allowed claims cover a pharmaceutical composition comprising MN-001 (tipelukast) for reducing a triglyceride blood level, reducing a total cholesterol blood level, and reducing a low-density lipoprotein (LDL) blood level. The allowed claims cover oral administration including liquid and solid dosage forms, and a wide range of doses of MN-001 and a range of different dosing frequencies. Shares down 2% premarket at $2.37. Recently, MNOV secured Canadian and European patent for MN-001 for hepatic ballooning.

For further details see:

MediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterol